Accelerate Diagnostics Q2 EPS $(0.50) Beats $(0.55) Estimate, Sales $2.99M Miss $3.01M Estimate
Portfolio Pulse from Benzinga Newsdesk
Accelerate Diagnostics (NASDAQ:AXDX) reported Q2 EPS of $(0.50), beating the estimate of $(0.55), and sales of $2.99M, missing the estimate of $3.01M. EPS improved significantly from $(2.97) last year, while sales saw a slight increase from $2.92M.
August 08, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Accelerate Diagnostics reported better-than-expected Q2 EPS of $(0.50), beating the $(0.55) estimate, but missed sales estimates slightly with $2.99M. EPS showed significant improvement from last year.
The better-than-expected EPS and significant improvement from last year's losses are positive indicators for investors. The slight miss in sales is less impactful given the overall positive earnings report.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100